Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Aberrant expression of glycogen synthase kinase-3β in human breast and head and neck cancer.

Ugolkov AV, Matsangou M, Taxter TJ, O'Halloran TV, Cryns VL, Giles FJ, Mazar AP.

Oncol Lett. 2018 Nov;16(5):6437-6444. doi: 10.3892/ol.2018.9483. Epub 2018 Sep 21.

2.

Human Organoids Share Structural and Genetic Features with Primary Pancreatic Adenocarcinoma Tumors.

Romero-Calvo I, Weber CR, Ray M, Brown M, Kirby K, Nandi RK, Long TM, Sparrow SM, Ugolkov A, Qiang W, Zhang Y, Brunetti T, Kindler H, Segal JP, Rzhetsky A, Mazar AP, Buschmann MM, Weichselbaum R, Roggin K, White KP.

Mol Cancer Res. 2019 Jan;17(1):70-83. doi: 10.1158/1541-7786.MCR-18-0531. Epub 2018 Aug 31.

PMID:
30171177
3.

9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

Ugolkov AV, Bondarenko GI, Dubrovskyi O, Berbegall AP, Navarro S, Noguera R, O'Halloran TV, Hendrix MJ, Giles FJ, Mazar AP.

Anticancer Drugs. 2018 Sep;29(8):717-724. doi: 10.1097/CAD.0000000000000652.

PMID:
29846250
4.

Macrogenomic engineering via modulation of the scaling of chromatin packing density.

Almassalha LM, Bauer GM, Wu W, Cherkezyan L, Zhang D, Kendra A, Gladstein S, Chandler JE, VanDerway D, Seagle BL, Ugolkov A, Billadeau DD, O'Halloran TV, Mazar AP, Roy HK, Szleifer I, Shahabi S, Backman V.

Nat Biomed Eng. 2017 Nov;1(11):902-913. doi: 10.1038/s41551-017-0153-2. Epub 2017 Nov 6.

5.

GSK-3β inhibitor, 9-ING-41, reduces cell viability and halts proliferation of B-cell lymphoma cell lines as a single agent and in combination with novel agents.

Karmali R, Chukkapalli V, Gordon LI, Borgia JA, Ugolkov A, Mazar AP, Giles FJ.

Oncotarget. 2017 Nov 11;8(70):114924-114934. doi: 10.18632/oncotarget.22414. eCollection 2017 Dec 29.

6.

Differential Response of Glioma Stem Cells to Arsenic Trioxide Therapy Is Regulated by MNK1 and mRNA Translation.

Bell JB, Eckerdt F, Dhruv HD, Finlay D, Peng S, Kim S, Kroczynska B, Beauchamp EM, Alley K, Clymer J, Goldman S, Cheng SY, James CD, Nakano I, Horbinski C, Mazar AP, Vuori K, Kumthekar P, Raizer J, Berens ME, Platanias LC.

Mol Cancer Res. 2018 Jan;16(1):32-46. doi: 10.1158/1541-7786.MCR-17-0397. Epub 2017 Oct 17.

7.

Discovery of the Antitumor Effects of a Porphyrazine Diol (Pz 285) in MDA-MB-231 Breast Tumor Xenograft Models in Mice.

Kandela IK, McAuliffe KJ, Cochran LE, Barrett AGM, Hoffman BM, Mazar AP, Trivedi ER.

ACS Med Chem Lett. 2017 Jun 29;8(7):705-709. doi: 10.1021/acsmedchemlett.7b00063. eCollection 2017 Jul 13.

8.

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.

de Geus SW, Baart VM, Boonstra MC, Kuppen PJ, Prevoo HA, Mazar AP, Bonsing BA, Morreau H, van de Velde CJ, Vahrmeijer AL, Sier CF.

Biomark Insights. 2017 Jun 22;12:1177271917715443. doi: 10.1177/1177271917715443. eCollection 2017. Review.

9.

Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.

Ugolkov A, Qiang W, Bondarenko G, Procissi D, Gaisina I, James CD, Chandler J, Kozikowski A, Gunosewoyo H, O'Halloran T, Raizer J, Mazar AP.

Transl Oncol. 2017 Aug;10(4):669-678. doi: 10.1016/j.tranon.2017.06.003. Epub 2017 Jun 30.

10.

Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation.

Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, Kachman M, May JL, Bartom E, Hua Y, Mishra RK, Schiltz GE, Dubrovskyi O, Mazar AP, Peter ME, Zheng H, James CD, Burant CF, Chandel NS, Davuluri RV, Horbinski C, Stegh AH.

Cell Rep. 2017 May 30;19(9):1858-1873. doi: 10.1016/j.celrep.2017.05.014.

11.

Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer.

Boonstra MC, Van Driel PBAA, Keereweer S, Prevoo HAJM, Stammes MA, Baart VM, Löwik CWGM, Mazar AP, van de Velde CJH, Vahrmeijer AL, Sier CFM.

Oral Oncol. 2017 Mar;66:1-8. doi: 10.1016/j.oraloncology.2016.12.026. Epub 2017 Jan 4.

PMID:
28249642
12.

Molecular Pathways: Revisiting Glycogen Synthase Kinase-3β as a Target for the Treatment of Cancer.

Walz A, Ugolkov A, Chandra S, Kozikowski A, Carneiro BA, O'Halloran TV, Giles FJ, Billadeau DD, Mazar AP.

Clin Cancer Res. 2017 Apr 15;23(8):1891-1897. doi: 10.1158/1078-0432.CCR-15-2240. Epub 2017 Jan 4. Review.

13.

Targeting melanoma with front-line therapy does not abrogate Nodal-expressing tumor cells.

Hendrix MJ, Kandela I, Mazar AP, Seftor EA, Seftor RE, Margaryan NV, Strizzi L, Murphy GF, Long GV, Scolyer RA.

Lab Invest. 2017 Feb;97(2):176-186. doi: 10.1038/labinvest.2016.107. Epub 2016 Oct 24.

14.

Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.

Yang D, Severin GW, Dougherty CA, Lombardi R, Chen D, Van Dort ME, Barnhart TE, Ross BD, Mazar AP, Hong H.

Oncotarget. 2016 Nov 8;7(45):73912-73924. doi: 10.18632/oncotarget.12528.

15.

GSK-3 inhibition overcomes chemoresistance in human breast cancer.

Ugolkov A, Gaisina I, Zhang JS, Billadeau DD, White K, Kozikowski A, Jain S, Cristofanilli M, Giles F, O'Halloran T, Cryns VL, Mazar AP.

Cancer Lett. 2016 Oct 1;380(2):384-92. doi: 10.1016/j.canlet.2016.07.006. Epub 2016 Jul 14.

16.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.

Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1.

17.

Melanoma Cells Block PEDF Production in Fibroblasts to Induce the Tumor-Promoting Phenotype of Cancer-Associated Fibroblasts.

Nwani NG, Deguiz ML, Jimenez B, Vinokour E, Dubrovskyi O, Ugolkov A, Mazar AP, Volpert OV.

Cancer Res. 2016 Apr 15;76(8):2265-76. doi: 10.1158/0008-5472.CAN-15-2468. Epub 2016 Feb 26.

18.

Patient-Derived Tumor Xenografts Are Susceptible to Formation of Human Lymphocytic Tumors.

Bondarenko G, Ugolkov A, Rohan S, Kulesza P, Dubrovskyi O, Gursel D, Mathews J, O'Halloran TV, Wei JJ, Mazar AP.

Neoplasia. 2015 Sep;17(9):735-741. doi: 10.1016/j.neo.2015.09.004.

19.

Virtual High-Throughput Screening To Identify Novel Activin Antagonists.

Zhu J, Mishra RK, Schiltz GE, Makanji Y, Scheidt KA, Mazar AP, Woodruff TK.

J Med Chem. 2015 Jul 23;58(14):5637-48. doi: 10.1021/acs.jmedchem.5b00753. Epub 2015 Jul 7.

20.

uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery.

Boonstra MC, van Driel PB, van Willigen DM, Stammes MA, Prevoo HA, Tummers QR, Mazar AP, Beekman FJ, Kuppen PJ, van de Velde CJ, Löwik CW, Frangioni JV, van Leeuwen FW, Sier CF, Vahrmeijer AL.

Oncotarget. 2015 Jun 10;6(16):14260-73.

21.

Biodistribution and in vivo toxicity of aptamer-loaded gold nanostars.

Dam DH, Culver KS, Kandela I, Lee RC, Chandra K, Lee H, Mantis C, Ugolkov A, Mazar AP, Odom TW.

Nanomedicine. 2015 Apr;11(3):671-9. doi: 10.1016/j.nano.2014.10.005. Epub 2014 Nov 18.

22.

NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.

Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD.

Mol Cancer Ther. 2014 Dec;13(12):2919-29. doi: 10.1158/1535-7163.MCT-14-0306. Epub 2014 Oct 13.

23.

Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.

Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E.

J Clin Invest. 2014 Oct;124(10):4614-28. doi: 10.1172/JCI74778. Epub 2014 Sep 9.

24.

α5β1 integrin signaling mediates oxidized low-density lipoprotein-induced inflammation and early atherosclerosis.

Yurdagul A Jr, Green J, Albert P, McInnis MC, Mazar AP, Orr AW.

Arterioscler Thromb Vasc Biol. 2014 Jul;34(7):1362-73. doi: 10.1161/ATVBAHA.114.303863. Epub 2014 May 15.

25.

The copper chelator ATN-224 induces caspase-independent cell death in diffuse large B cell lymphoma.

Lee K, Hart MR, Briehl MM, Mazar AP, Tome ME.

Int J Oncol. 2014 Jul;45(1):439-47. doi: 10.3892/ijo.2014.2396. Epub 2014 Apr 23.

26.

Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study.

Boonstra MC, Verbeek FP, Mazar AP, Prevoo HA, Kuppen PJ, van de Velde CJ, Vahrmeijer AL, Sier CF.

BMC Cancer. 2014 Apr 17;14:269. doi: 10.1186/1471-2407-14-269.

27.

Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

Xu X, Cai Y, Wei Y, Donate F, Juarez J, Parry G, Chen L, Meehan EJ, Ahn RW, Ugolkov A, Dubrovskyi O, O'Halloran TV, Huang M, Mazar AP.

PLoS One. 2014 Jan 21;9(1):e85349. doi: 10.1371/journal.pone.0085349. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e99911.

28.

Targeting SOD1 reduces experimental non–small-cell lung cancer.

Glasauer A, Sena LA, Diebold LP, Mazar AP, Chandel NS.

J Clin Invest. 2014 Jan;124(1):117-28.

29.

Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.

Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O'Halloran TV, Lengyel E.

Mol Cancer Ther. 2013 Dec;12(12):2628-39. doi: 10.1158/1535-7163.MCT-13-0204. Epub 2013 Sep 23.

30.

The many spaces of uPAR: delivery of theranostic agents and nanobins to multiple tumor compartments through a single target.

O'Halloran TV, Ahn R, Hankins P, Swindell E, Mazar AP.

Theranostics. 2013 Jun 25;3(7):496-506. doi: 10.7150/thno.4953. Print 2013. Review.

31.

Biologic role of the plasminogen-plasmin system: thrombolysis, bleeding, and beyond.

Kwaan HC, Mazar AP.

Semin Thromb Hemost. 2013 Jun;39(4):327-8. doi: 10.1055/s-0033-1343616. Epub 2013 May 27. No abstract available.

PMID:
23712353
32.

The apparent uPA/PAI-1 paradox in cancer: more than meets the eye.

Kwaan HC, Mazar AP, McMahon BJ.

Semin Thromb Hemost. 2013 Jun;39(4):382-91. doi: 10.1055/s-0033-1338127. Epub 2013 Mar 26. Review.

PMID:
23532574
33.

Nano-encapsulation of arsenic trioxide enhances efficacy against murine lymphoma model while minimizing its impact on ovarian reserve in vitro and in vivo.

Ahn RW, Barrett SL, Raja MR, Jozefik JK, Spaho L, Chen H, Bally MB, Mazar AP, Avram MJ, Winter JN, Gordon LI, Shea LD, O'Halloran TV, Woodruff TK.

PLoS One. 2013;8(3):e58491. doi: 10.1371/journal.pone.0058491. Epub 2013 Mar 20.

34.

The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies.

Lee K, Briehl MM, Mazar AP, Batinic-Haberle I, Reboucas JS, Glinsmann-Gibson B, Rimsza LM, Tome ME.

Free Radic Biol Med. 2013 Jul;60:157-67. doi: 10.1016/j.freeradbiomed.2013.02.003. Epub 2013 Feb 14.

35.

Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge CA, Yu JG, Powell K, Mazar AP, Teknos TN, Chiocca EA, Glorioso JC, Old M, Kaur B.

Clin Cancer Res. 2012 Sep 15;18(18):4931-41. Epub 2012 Jul 2.

36.

Lipoprotein receptor-related protein 1 regulates collagen 1 expression, proteolysis, and migration in human pleural mesothelial cells.

Tucker TA, Williams L, Koenig K, Kothari H, Komissarov AA, Florova G, Mazar AP, Allen TC, Bdeir K, Mohan Rao LV, Idell S.

Am J Respir Cell Mol Biol. 2012 Feb;46(2):196-206. doi: 10.1165/rcmb.2011-0071OC.

38.

Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.

Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E.

Clin Cancer Res. 2011 Feb 1;17(3):459-71. doi: 10.1158/1078-0432.CCR-10-2258. Epub 2010 Dec 13.

39.

An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.

Rabbani SA, Ateeq B, Arakelian A, Valentino ML, Shaw DE, Dauffenbach LM, Kerfoot CA, Mazar AP.

Neoplasia. 2010 Oct;12(10):778-88.

40.

Redox-related antimelanoma activity of ATN-224.

Trapp V, Lee K, Doñate F, Mazar AP, Fruehauf JP.

Melanoma Res. 2009 Dec;19(6):350-60. doi: 10.1097/CMR.0b013e32832c6324.

PMID:
22760066
41.

Regulation of intrapleural fibrinolysis by urokinase-alpha-macroglobulin complexes in tetracycline-induced pleural injury in rabbits.

Komissarov AA, Mazar AP, Koenig K, Kurdowska AK, Idell S.

Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297(4):L568-77. doi: 10.1152/ajplung.00066.2009. Epub 2009 Aug 7.

42.

The urokinase receptor supports tumorigenesis of human malignant pleural mesothelioma cells.

Tucker TA, Dean C, Komissarov AA, Koenig K, Mazar AP, Pendurthi U, Allen T, Idell S.

Am J Respir Cell Mol Biol. 2010 Jun;42(6):685-96. doi: 10.1165/rcmb.2008-0433OC. Epub 2009 Jul 27.

43.

Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.

Van Buren G 2nd, Gray MJ, Dallas NA, Xia L, Lim SJ, Fan F, Mazar AP, Ellis LM.

Cancer. 2009 Jul 15;115(14):3360-8. doi: 10.1002/cncr.24371.

44.

Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy.

Mazar AP.

Clin Cancer Res. 2008 Sep 15;14(18):5649-55. doi: 10.1158/1078-0432.CCR-07-4863. Review.

45.

Superoxide dismutase 1 (SOD1) is essential for H2O2-mediated oxidation and inactivation of phosphatases in growth factor signaling.

Juarez JC, Manuia M, Burnett ME, Betancourt O, Boivin B, Shaw DE, Tonks NK, Mazar AP, Doñate F.

Proc Natl Acad Sci U S A. 2008 May 20;105(20):7147-52. doi: 10.1073/pnas.0709451105. Epub 2008 May 14.

46.

Pharmacology of the novel antiangiogenic peptide ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose-response curve in several preclinical models of angiogenesis and tumor growth.

Doñate F, Parry GC, Shaked Y, Hensley H, Guan X, Beck I, Tel-Tsur Z, Plunkett ML, Manuia M, Shaw DE, Kerbel RS, Mazar AP.

Clin Cancer Res. 2008 Apr 1;14(7):2137-44. doi: 10.1158/1078-0432.CCR-07-4530.

47.

Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes.

Huai Q, Zhou A, Lin L, Mazar AP, Parry GC, Callahan J, Shaw DE, Furie B, Furie BC, Huang M.

Nat Struct Mol Biol. 2008 Apr;15(4):422-3. doi: 10.1038/nsmb.1404. Epub 2008 Mar 23.

48.

Identification of biomarkers for the antiangiogenic and antitumour activity of the superoxide dismutase 1 (SOD1) inhibitor tetrathiomolybdate (ATN-224).

Doñate F, Juarez JC, Burnett ME, Manuia MM, Guan X, Shaw DE, Smith EL, Timucin C, Braunstein MJ, Batuman OA, Mazar AP.

Br J Cancer. 2008 Feb 26;98(4):776-83. doi: 10.1038/sj.bjc.6604226. Epub 2008 Feb 5.

49.

Evaluating distant metastases in breast cancer: from biology to outcomes.

Rabbani SA, Mazar AP.

Cancer Metastasis Rev. 2007 Dec;26(3-4):663-74. Review.

PMID:
17823779
50.

Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA.

Shetty S, Velusamy T, Idell S, Shetty P, Mazar AP, Bhandary YP, Shetty RS.

Mol Cell Biol. 2007 Aug;27(16):5607-18. Epub 2007 Jun 4.

Supplemental Content

Loading ...
Support Center